High-Flow Oxygen Lowers Intubation but Does Not Improve Survival

Acute hypoxemic respiratory failure remains a leading cause of intensive care admission, prompting widespread reliance on noninvasive oxygenation strategies to avoid the complications of mechanical ventilation [1]. Over the past decade, high-flow nasal cannula therapy has surged in popularity, driven by early trials suggesting it might reduce both intubation rates and mortality compared to conventional oxygen therapy [2, 3]. However, subsequent systematic reviews have yielded conflicting results, with several analyses confirming a reduction in intubation but failing to demonstrate a definitive survival benefit [4, 5]. This discrepancy has left clinicians uncertain about the true mortality impact of high-flow oxygen in critically ill patients. A newly published multicenter trial now provides rigorous data to clarify the clinical outcomes of high-flow versus standard oxygen therapy.